Type 2 Diabetes Serum

In Stock Samples

Lot # Condition Volume Race/Ethnicity Age Gender Country of Collection Medications Vials Price Action
79687 Diabetes Type II 1.0 ML Asian/Pacific Islander 64 Male United States
Metformin HCL 1000mg 2/day Atonvastatin Calcium 20mg 1/day Cholecalcif 50MCG 1/day Tamsulosin HCL0.4 MG 1/day Finasteride 5 MG 1/day
4 $316.00
77414 Diabetes Type II 1.0 ML African American 68 Male United States
Alopurinol 100mg QD Atorvastatin 20mg QD Tamsulosin 4mg QD
4 $316.00
64605 Diabetes Type II 1.0 ML African American 68 Male United States
Alopurinol 100mg QD Atorvastatin 20mg QD Tamsulosin 4mg QD
5 $316.00
67500 Diabetes Type II 1.0 ML Caucasian 54 Male United States
Jardiance 25mg QD, Metformin 1,000mg BID, Insulin, Fenofibric acid 135mg QD Crestor 10mg QD, Cozar 25mg QD
5 $316.00
65314 Diabetes Type II 1.0 ML Hispanic/Latino 43 Male United States
Insulin Levothyroxine 75mg Aspirin 81mg Fish oil supplement Mirtazapine 30mg QD Atorvastatin 40mg Jardiance 10mg Stopped 4 months ago Trulicity
5 $316.00
64332 Diabetes Type II 1.0 ML African American 53 Male United States
Metformin 1,000mg BID Atorvastatin 20mg QD
4 $316.00

Human Type 2 Diabetes Serum for Metabolic and Endocrine Research

Our Type 2 Diabetes Serum is sourced from IRB-consented donors clinically diagnosed with type 2 diabetes (T2D). Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for metabolic, endocrine and biomarker research. Type 2 diabetes is a metabolic disease characterised by insulin resistance in liver, muscle and adipose tissue together with progressive beta-cell secretory failure — a fundamentally different mechanism from the autoimmune beta-cell destruction of type 1 diabetes.

Why Serum for Type 2 Diabetes Research

  • Serum is the conventional matrix for the endocrine axis of T2D: insulin, C-peptide and proinsulin measurements support work on residual beta-cell secretory capacity and on the degree of insulin resistance.
  • Adipose tissue is an endocrine organ in T2D. Adipokines such as leptin and adiponectin, and the adipose-derived inflammatory mediators TNF-alpha and IL-6, are measurable in serum and underpin the concept of metabolic inflammation — a chronic low-grade inflammatory state driven by nutrient excess rather than by autoimmunity.
  • High-sensitivity CRP and related acute-phase reactants link that low-grade inflammation to the elevated cardiovascular risk that dominates T2D outcomes.
  • Serum supports the full clinical chemistry panel relevant to diabetic complications in a single matrix: lipid fractions, creatinine for eGFR estimation, and liver enzymes relevant to concurrent metabolic liver disease.
  • Because serum lacks anticoagulant, it is well suited to immunoassay and mass spectrometry platforms where citrate or EDTA carryover interferes, and it is the matrix in which most published diabetes biomarker reference data were generated.
  • Advanced glycation end-products and glycated protein species accumulate systemically in sustained hyperglycaemia and can be interrogated in serum alongside conventional glycaemic indices.

Donor Stratification Available

  • Glycaemic control band by most recent HbA1c, where reported
  • Treatment class: lifestyle/diet-managed, metformin monotherapy, GLP-1 receptor agonist, SGLT2 inhibitor, sulfonylurea, or insulin-treated
  • Disease duration since diagnosis
  • BMI and obesity class
  • Complication status: diabetic kidney disease, retinopathy, or peripheral neuropathy where documented
  • Cardiometabolic comorbidity: hypertension, dyslipidaemia, metabolic liver disease
  • Matched healthy controls available

Product Features

  • Collected from clinically confirmed T2D donors
  • Research Use Only (RUO)
  • Processed and frozen within 24 hours of collection
  • IRB-approved protocols with documented consent
  • Custom aliquot volumes available upon request
  • Longitudinal collections from the same donor available by request

De-identified Donor Data

  • Diagnosis confirmation
  • Age, sex assigned at birth, and race/ethnicity
  • Donor-reported medications, allergy and infectious disease history
  • Comorbidities and treatment history where available
  • Additional T2D-specific metadata available on request

Applications

  • Insulin, C-peptide and proinsulin measurement for insulin resistance and beta-cell function research
  • Adipokine profiling, including leptin and adiponectin
  • Metabolic inflammation studies using TNF-alpha, IL-6 and high-sensitivity CRP
  • Lipidomic and metabolomic profiling of dysglycaemia
  • Biomarker discovery for diabetic kidney disease and other microvascular complications
  • Diagnostic and companion-assay development using disease-state serum as a clinically relevant matrix
  • Proteomic comparison of treatment-naive versus pharmacologically treated donors
  • Therapeutic candidate screening and target validation in metabolic disease

Other Type 2 Diabetes Specimen Types

Compliance and Quality Assurance

  • IRB-approved and HIPAA-compliant protocols
  • Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
  • Documentation support available for regulatory review

Ordering & Customization

Type 2 diabetes serum is available in standard and custom volumes. For pricing, availability, or to discuss a stratified cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse serum across all disease states and healthy donors, visit our human serum page.

Protocols & Documentation

  • Serum Isolation

    Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Serum

Frequently Asked Questions

×

Ask a Question

Need a custom Serum cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information